Monte Rosa Therapeutics UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. Good morning, everybody. Good afternoon. Welcome to the next session at the UBS Global Biopharma Conference. I'm Alice Nettleton, one of the SMID biotech analysts at UBS. Happy to introduce Monte Rosa Therapeutics. We have with us Markus Warmuth, Chief Executive Officer. Great to see you, Markus. Thank you so much for joining us.
Yeah, great to see you, and thanks for inviting us to your conference here.
Yeah, absolutely. To start with, would you like to give a brief overview of the company and of your QuEEN Molecular Glue degrader platform for those who may be newer to the story, and then we can get into some Q&A?
Yeah, no, happy to. Monte Rosa, still a fairly young company. We're about seven years old now. You can tell from the name, we originated in Switzerland, although we're now headquartered in the U.S. We're doing targeted protein degradation. As you know, there's different ways of doing it. There's a modality called PROTACs. That's what we're not doing, sort of heterobifunctional molecules that bind to the protein destruction complex and something you want to destroy. Our molecules are a bit more complex, although they're technically smaller. They're small molecules that essentially bind to a ubiquitin ligase, which is part of that protein destruction complex, and reshape its surface to induce a protein-protein interaction with the target we want to get rid of. For us, it really opened up a lot of opportunities around targets that others are just flat out not able to go after.
VAV1, which we probably will touch on, is one of the best examples for them.
Great. I wanted to start with MRT-8102, which is your wholly owned NEK7 degrader.
Moving into phase II. Just to start with, when you think about NEK7 degradation versus direct NLRP3 inhibition, what are the key advantages of your approach, and are you aiming to achieve better efficacy or safety, or?
Yeah, we are now in the NLRP3 inflammasome, which obviously is a hot pathway, also a contested one, which I am sure we will talk about in a second. There are two ways you can inhibit the NLRP3 inflammasome. You have a direct inhibitor, or, as in our case, a NEK7 degrader. What does a NEK7 degrader, 8102, do? NEK7 actually is an essential scaffolding protein for the NLRP3 inflammasome. Essentially, there is no NEK7, there is no active, fully assembled inflammasome, and we like that, of course, better than the on and off inhibition that you get with inhibitors. We also think that provides for better safety margins, because we can make our degraders exquisitely selective, and we can actually test it on a cellular level through proteomics. We know that 8102 degrades NEK7 and nothing else across multiple different cell types we have tested.
For NLRP3 inhibitors, best case, you have some other ATPase biochemical assays, but you really can test selectivity across 10,000, 20,000 proteins in a cell. We are super confident in general when we go into the clinic about the level of selectivity, and then, of course, also safety. The last point to make is, when you degrade, the protein is gone, the pathway is shut down, it does not necessarily typically not come back. You do get much deeper, more prolonged PD, which obviously we think will translate into better efficacy.
Great. Very topical is the ZEUS dataset. There was recently at AHA the full dataset from Novo Nordisk with their IL-6 program, which was very relevant to you guys in the broader NLRP3 space as well. It would be interesting to hear your perspective on that and the implications for upstream approaches, including your approach.
Yeah. Yeah. I mean, obviously, ZEUS and the data release sent shockwaves through the fields.
I will always remember the date was July 31st. That is how dramatic this was for us. That said, true, we were always a little skeptical around the IL-6 targeting. If you think about the pathway, the NLRP3 pathway, IL-6 is very far downstream. It is literally the last step before you essentially synthesize and release CRP from the liver, and it was unclear to us how that feeds back into active inflammation in atherosclerotic plaques. A week or two after the actual data was presented at AHA, I think it became, or is even more clear why the trial did not succeed, and I think it is really a combination of what I just said, maybe not the best target to go after, plus maybe not the best drug.
It was interesting to see that the antibody left about 25% IL-6 in the system. It reduced IL-6 levels by 75%. I would have expected 90% and greater for an antibody. There were clearly some issues around, actually not some big issues around the trial design. I think there was an obsession around selecting for high CRP levels. Probably that led to the idea of selecting patients with chronic kidney disease, CKD. That alone actually, of course, increases your CRP levels. Many of the patients, the majority, vast majority were obese, so you now have inflammation coming from the liver. Of course, when you end up with a CRP level of greater than three milligrams per liter, now you do not know, okay, how much is from the kidney, from the liver, or an active atherosclerotic plaque.
Many of the patients going into this trial might not even have had an ongoing ASCVD issue. I think between these three things, probably not a shocker that the trial was negative, which translates into we still have very, very high conviction around the pathway, the level of validation between increased lipids, oxidized LDL, oxidized cholesterol, and triggering the NLRP3 pathways rock solid. I think if you have the right trial design, you really find the patients that still have remaining inflammatory risk in ASCVD, you will be absolutely successful.
After AHA, I know there was also some conversation about this at ESC. Do you feel like industry and physician community are kind of coming round to the idea that NLRP3 and then NEK7 should be interrogated as the next targets? Or is that kind of slower moving?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
